Aggressive lipid-lowering treatment approaches for vulnerable plaque in coronary artery with rosuvastatin. -Assessment using angioscopy and intravascular ultrasound -

Trial Profile

Aggressive lipid-lowering treatment approaches for vulnerable plaque in coronary artery with rosuvastatin. -Assessment using angioscopy and intravascular ultrasound -

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ALTAIR
  • Most Recent Events

    • 28 Jan 2016 As per an advice from the Independent Data Monitoring Committee after an assessment at week 48, this trial was terminated in April 2013, according to an article published in the The American Journal of Cardiology.
    • 28 Jan 2016 Results published in the American Journal of Cardiology
    • 20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top